MetaCap

Rhythm Pharmaceuticals (RYTM) vs TG Therapeutics (TGTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TG Therapeutics (TGTX) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 98.2% versus a gain of 10.4%. Over five years, RYTM leads with a +1116.0% price change compared with +164.1% for TGTX. TG Therapeutics is the larger company by market cap ($9.57 billion vs $7.79 billion), about 1.2 times the size.

TG Therapeutics converts more of its revenue into profit, with a net margin of 72.6% versus -103.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RYTM+10.44%TGTX+98.25%
+114%+41%-32%
Nov 21, 20251 yearNov 20, 2026
RYTM+990.87%TGTX+159.48%
+1078%+470%-139%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RYTM versus TGTX key metrics
MetricRYTMTGTX
Share price$112.36$63.34
Market cap$7.79B$9.57B
1-day change-3.80%-2.37%
YTD return+4.97%+112.48%
1-year return+10.44%+98.25%
5-year return+1116.02%+164.14%
P/E ratio (TTM)—94.54
Forward P/E—24.81
EPS (TTM)$-2.91$0.67
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$189.76M$616.29M
Revenue growth (YoY)+45.83%+87.32%
Net income (latest FY)$-196.54M$447.18M
Gross margin89.73%83.66%
Operating margin-101.19%20.01%
Net margin-103.57%72.56%
52-week high$122.20$68.03
52-week low$74.50$26.76
Distance from 52-week high-8.05%-6.89%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+24.71%+9.61%
Average volume1.10M1.86M
Shares outstanding69.33M151.15M
Employees414399
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TGTX has outperformed RYTM by 87.8 percentage points over the past year.
  • TG Therapeutics is more profitable, keeping 72.6 cents of every revenue dollar as net income versus -103.6 cents for Rhythm Pharmaceuticals.
  • TG Therapeutics grew revenue faster in its latest fiscal year (+87.32% vs +45.83%).

About Rhythm Pharmaceuticals

RYTM stock →

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees

About TG Therapeutics

TGTX stock →

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees

RYTM vs TGTX FAQ

Which is bigger, Rhythm Pharmaceuticals or TG Therapeutics?

TG Therapeutics (TGTX) is larger, with a market capitalization of $9.57B compared with $7.79B for Rhythm Pharmaceuticals (RYTM).

Which stock has performed better over the past year, RYTM or TGTX?

TGTX returned +98.25% over the past 12 months, compared with +10.44% for RYTM (price return, excluding dividends). Past performance does not predict future results.

Are Rhythm Pharmaceuticals and TG Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons